Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.
Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.
Delcath Systems (Nasdaq: DCTH) announced its participation in two upcoming virtual investor conferences. The first is the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022, at 11:00 AM ET, which will not be webcast. The second event is the 2022 SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 AM ET, which will be available via webcast. Delcath focuses on interventional oncology, particularly using its proprietary PHP system for treating liver cancers.
Delcath Systems (Nasdaq: DCTH) announced the appointment of Anthony Dias as the new Vice President of Finance. Bringing over 20 years of financial leadership experience in the healthcare sector, Dias will oversee the company's financial planning, reporting, accounting, and treasury. Previously, he held senior finance roles at Advanced Group and PAREXEL, where he was instrumental in a $5.5 billion sale. Alongside his appointment, Delcath granted him options to purchase 30,000 shares, with a vesting schedule linked to his continued employment.
Delcath Systems announced promising results from a retrospective study on the use of its CHEMOSAT® Hepatic Delivery System for patients with liver dominant metastatic uveal melanoma. The study revealed a hepatic disease control rate of 88.9%, a hepatic response rate of 66.7%, and an overall response rate of 60.5% across 81 patients. Following a median follow-up of 12.9 months, the median progression-free survival (PFS) was 8.4 months and overall survival (OS) was 14.9 months. The study emphasized a favorable safety profile with no fatal treatment-related adverse events.
Delcath Systems, Inc. (NASDAQ: DCTH) has appointed David Hoffman as General Counsel and Corporate Secretary. Hoffman brings over 20 years of biotechnology legal experience, previously serving at Vericel Corporation and Sunovion Pharmaceuticals. His expertise spans healthcare law, compliance, and business transactions. CEO Gerard Michel emphasized Hoffman's contributions as essential for advancing Delcath's mission to commercialize therapies targeting liver cancers. Delcath focuses on innovative treatments including the HEPZATO KIT, designed for localized chemotherapy delivery.
Delcath Systems (DCTH), an interventional oncology company, has announced its participation in the H.C. Wainwright BioConnect Virtual Investor Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Delcath will also hold one-on-one investor meetings during the event. The company focuses on innovative treatments for liver cancers, utilizing its proprietary percutaneous hepatic perfusion system, HEPZATO, in the U.S. and CHEMOSAT in Europe.
Delcath Systems announced encouraging results from the phase 3 FOCUS study of its treatment HEPZATO for metastatic ocular melanoma.
The study showed a median duration of response of 14 months, with an overall response rate (ORR) of 31.4% and a 12-month survival hazard ratio (HR) of 0.37 (p=0.01) compared to the Best Alternative Care (BAC) arm.
HEPZATO also demonstrated a disease control rate of 65.7% and improved progression-free survival (PFS) compared to BAC. A new NDA submission is anticipated by mid-2022.
Delcath Systems, Inc. (Nasdaq: DCTH) announced an upcoming Investor Update Meeting on December 2, 2021, focusing on its investigational drug/device combination product, HEPZATO KIT. The meeting will feature discussions on the FOCUS trial results and the clinical experience with CHEMOSAT, detailing unmet needs in treating liver cancers. A panel of leading physicians will present key topics including PHP quality of life and future clinical development plans. This event underscores Delcath's commitment to innovative solutions for liver cancer treatment.
Delcath Systems (Nasdaq: DCTH) reported its Q3 2021 results, highlighting key developments including a $20 million debt facility and FDA approval for an expanded access protocol for HEPZATO™ Kit. Product revenue increased to $522,000, up from $466,000 year-over-year. However, the company faced a net loss of $7.1 million compared to $5.0 million in Q3 2020. Operating expenses rose to $7.0 million, influenced by stock option expenses. Cash reserves improved to $29 million from $11.1 million a year prior. Delcath plans to file its HEPZATO NDA mid-2022 and hosted an investor update on December 2.
Delcath Systems, a company specializing in interventional oncology, announced its participation in the Canaccord Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. The event will consist of one-on-one meetings only. Delcath focuses on treating rare liver cancers using its proprietary percutaneous hepatic perfusion (PHP) system, marketed in the U.S. as HEPZATO KIT and in Europe as CHEMOSAT. This innovative system administers high-dose chemotherapy directly to the liver while minimizing systemic side effects.
Delcath Systems (DCTH) will host an Investor Update on December 2, 2021, from 10 AM to 1 PM ET, focusing on its Hepzato Kit and its applications in treating liver cancers. Physicians will present updated data from the Focus trial and discuss the potential of Hepzato in treating hepatic-dominant metastatic ocular melanoma, colorectal cancer, and intrahepatic cholangiocarcinoma. The event will be accessible via a live webcast, with the archive available afterward on the company's website.